## Highlights of This Issue 5145

### SPECIAL FEATURES

#### CCR Translations
- **5147** Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!
  Maria G. Castro, Gregory J. Baker, and Pedro R. Lowenstein  
  See related article, p. 5290

#### CCR New Strategies
- **5150** New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances
  Joyce Liu and Ursula A. Matulonis

#### Molecular Pathways
- **5157** Molecular Pathways: Myeloid Complicity in Cancer
  Ingunn M. Stromnes, Philip D. Greenberg, and Sunil R. Hingorani

#### CCR Focus
- **5172** The Lymphoma Medicine Cabinet
  Susan E. Bates

- **5173** Putting the Clinical and Biological Heterogeneity of Non-Hodgkin Lymphoma into Context
  Owen A. O’Connor and Kensei Tobinai

- **5182** Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype
  Kieron Dunleavy, Mark Roschewski, and Wyndham H. Wilson

- **5194** New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?
  Martin Dreyling, Simone Ferrero, Niklas Vogt, and Wolfram Klappler on behalf of the European Mantle Cell Lymphoma Network

### CANCER THERAPY: CLINICAL
- **5255** A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies
  Timothy S. Pardee, King Lee, John Luddy, Claudia Maturo, Robert Rodriguez, Scott Isom, Lance D. Miller, Kristin M. Stadelman, Denise Levitan, David Hurd, Leslie R. Ellis, Robin Harrelson, Megan Manuel, Sarah Dralle, Susan Lyerly, and Bayard L. Powell

### PERSONALIZED MEDICINE AND IMAGING
- **5265** Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer
  Lajos Pusztai, Stacy Moulder, Mehmet Altan, Danielle Kwiatkowski, Vicente Valero, Naoto T. Ueno, Francisco J. Esteva, Rony Avritscher, Yuan Qi, Lewis Strauss, Gabriel N. Hortobagyi, Christos Hatzis, and W. Fraser Symmans
Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort
Trine Tramm, Hayat Mohammed, Simen Myhre, Marianne Kyndt, Jan Alsner, Anne-Lise Borresen-Dale, Therese Sørlie, Arnoldo Frigessi, and Jens Overgaard

Identification of Differentially Expressed Long Noncoding RNAs in Bladder Cancer
Stefan Peter, Edyta Borkowska, Ross M. Drayton, Callum P. Rakhit, Aidan Noon, Wei Chen, and James WF Catto

Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

Smoking and Risk of Low- and High-Grade Prostate Cancer: Results from the REDUCE Study
Tammy Ho, Lauren E. Howard, Adriana C. Vidal, Leah Gerber, Daniel Moreira, Madeleine McKeever, Gerald Andriole, Ramiro Castro-Santamaria, and Stephen J. Freedland

Correction: Targeting miR21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth

Table of Contents
ABOUT THE COVER

The cover shows the expression of long noncoding RNAs in normal and malignant bladder urothelium as detected by microarray. Unsupervised hierarchical clustering reveals discrimination of normal, low-grade and high-grade malignant tissues. For details, see the article by Peter and colleagues on page 5311 of this issue.